-
A First Take On Stemline's Pivotal BPDCN Study Patient Death
Friday, February 3, 2017 - 2:41pm | 429Read More...Despite a January 18 patient death during Stemline Therapeutics Inc (NASDAQ: STML)’s ongoing SL-401 trials, Ladenburg Thalmann reiterated a Buy rating on the company, the blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment study of which is continuing to enroll new participants....
